Editas Medicine Q2 2025: On track to file IND by mid-2026, proof-of-concept by year-end.

• Editas Medicine to select lead dev candidate in September • On track to file IND by mid-2026, human proof-of-concept by year-end 2026 • First IND/CTA accepted for CD19 HD Allo CAR T program with Bristol Myers Squibb • Milestone payment to Editas triggered • Presented data at ASGCT, TIDES, and EHA validating gene upregulation strategy and in vivo delivery platform technology • Strong cash position with operational runway into 2Q 2027

Cambridge, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported its financial results for the second quarter 2025 and provided business updates. The company made significant strides in executing its strategy, with key milestones expected in the coming quarters.

Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine, stated, "We made good progress in executing our strategy in the second quarter, driving towards our goal of nominating our first in vivo development candidate, which we plan to select in September. We are on track to file an IND for our lead program by mid-2026 and achieve human proof-of-concept by the end of 2026."

The company presented new preclinical proof-of-concept data at the American Society of Gene and Cell Therapy (ASGCT), TIDES, and European Hematology Association (EHA) 2025 Congress, validating the potential of its gene upregulation strategy and in vivo delivery platform technology. These data support the transformative potential of Editas’ LNP platform and differentiated upregulation strategy in treating serious diseases.

As part of its collaboration with Bristol Myers Squibb, the first IND/CTA was accepted for the CD19 HD Allo CAR T program, triggering a milestone payment to Editas. This marks the first time Editas’ in-house developed technology will be used clinically in the allogenic CAR-T setting for the potential treatment of autoimmune disease.

Editas Medicine reported a strong cash position, with operational runway into the second quarter of 2027. The company expects its existing cash, cash equivalents, marketable securities, and the retained portions of the payments payable under its license agreement with Vertex Pharmaceuticals to fund its operating expenses and capital expenditure requirements.

Financial Highlights for the Second Quarter 2025:
- Cash, cash equivalents, and marketable securities as of June 30, 2025, were $178.5 million compared to $269.9 million as of December 31, 2024.
- Net loss attributable to common stockholders was $53.2 million, or $0.63 per share, compared to net loss of $67.6 million, or $0.82 per share, for the same period in 2024.
- Collaboration and other research and development revenues increased to $3.6 million for the three months ended June 30, 2025, compared to $0.5 million for the same period in 2024.
- Research and development expenses decreased by $38.0 million to $16.2 million for the three months ended June 30, 2025, compared to $54.2 million for the same period in 2024.
- General and administrative expenses decreased by $5.3 million to $12.9 million for the three months ended June 30, 2025, compared to $18.2 million for the same period in 2024.

Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. The company is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.

For the latest information and scientific presentations, please visit www.editasmedicine.com.

References:
[1] https://www.morningstar.com/news/globe-newswire/9510569/editas-medicine-announces-second-quarter-2025-results-and-business-updates